Nehal KS, Bichakjian CK. Update on keratinocyte carcinomas. N Engl J Med. 2018;379(4):363–74. https://doi.org/10.1056/NEJMra1708701.

Article  CAS  PubMed  Google Scholar 

Hu W, Fang L, Ni R, et al. Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years. BMC Cancer. 2022;22(1):836. https://doi.org/10.1186/s12885-022-09940-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

National Comprehensive Cancer Center. NCCN Clinical practice guidelines in oncology: squamous cell skin cancer. Version 2.2022. May 2, 2022.

National Comprehensive Cancer Center. NCCN Clinical practice guidelines in oncology: Merkel cell carcinoma version 2.2022. March 24, 2022.

National Comprehensive Cancer Center. NCCN Clinical practice guidelines in oncology: basal cell carcinoma. Version 2.2022. March 24, 2022.

Schmalbach CE, Ow TJ, Choi KY, O’Leary M, Lin A, Hughley BB, Emerick KS, Moore B, Lee NY, Zandberg DP, Wang SJ. American Head and Neck Society position statement on the use of PD-1 inhibitors for treatment of advanced cutaneous squamous cell carcinoma. Head Neck. 2022. https://doi.org/10.1002/hed.27202.

Article  PubMed  Google Scholar 

Fraga SD, Besaw RJ, Murad F, et al. Complete margin assessment versus sectional assessment in surgically excised high-risk keratinocyte carcinomas: a systematic review and meta-analysis. Dermatol Surg. 2022;48(7):704–10.

Article  CAS  PubMed  Google Scholar 

Xiong DD, Beal BT, Varra V, et al. Outcomes in intermediate-risk squamous cell carcinomas treated with Mohs micrographic surgery compared with wide local excision. J Am Acad Dermatol. 2020;82(5):1195–204. https://doi.org/10.1016/j.jaad.2019.12.049.

Article  PubMed  Google Scholar 

Brodland DG, Zitelli JA. Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol. 1992;27(2 Pt 1):241–8. https://doi.org/10.1016/0190-9622(92)70178-i.

Article  CAS  PubMed  Google Scholar 

Stratigos AJ, Garbe C, Dessinioti C, et al. European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC). European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. Eur J Cancer. 2020;128:83–102. https://doi.org/10.1016/j.ejca.2020.01.008.

Article  CAS  PubMed  Google Scholar 

Keohane SG, Botting J, Budny PG, et al.; British Association of Dermatologists’ Clinical Standards Unit. British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020. Br J Dermatol. 2021 Mar;184(3):401–414. https://doi.org/10.1111/bjd.19621. Erratum in: Br J Dermatol. 2021 Sep;185(3):686. Erratum in: Br J Dermatol. 2022 Mar;186(3):596–597

Porceddu SV, Bressel M, Poulsen MG, et al. Postoperative concurrent chemoradiotherapy versus postoperative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: the randomized phase III TROG 0501 Trial. J Clin Oncol. 2018;36(13):1275–83. https://doi.org/10.1200/JCO.2017.77.0941.

Article  CAS  PubMed  Google Scholar 

Migden MR, Rischin D, Schmults CD, et al. PD-1 Blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341–51. This phase II study demonstrated the results of cemiplimab in advanced and metastatic cSCC leading to the first FDA approval of a PD-1 inhibitor for cSCC.

Article  CAS  PubMed  Google Scholar 

Grob JJ, Gonzalez R, Basset-Seguin N, et al. Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629). J Clin Oncol. 2020;38(25):2916–25. https://doi.org/10.1200/JCO.19.03054. The Keynote-629 study demonstrated the results of pembrolizumab in advanced and metastatic cSCC leading to FDA approval of pembrolizumab for cSCC.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Keeping S, Xu Y, Chen CI, et al. Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma. Future Oncol. 2021;17(5):611–27. https://doi.org/10.2217/fon-2020-0823.

Article  CAS  PubMed  Google Scholar 

Gross N, Ferrarotto R, Nagarajan P, et al. LBA74-phase II study of neoadjuvant cemiplimab prior to surgery in patients with stage III/IV (M0) cutaneous squamous cell carcinoma of the head and neck (CSCC-HN). Ann Oncol. 2019;30:v910.

Article  Google Scholar 

Gross ND, Miller DM, Khushalani NI, et al. Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med. 2022. https://doi.org/10.1056/NEJMoa2209813. Phase II study demonstrating positive effect of neoadjuvant cemiplimab in stage II-IV cSCC.

Article  PubMed  Google Scholar 

De Bruyn P, Van Gestel D, Ost P, et al. Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go? Curr Opin Oncol. 2019;31(2):54–64. https://doi.org/10.1097/CCO.0000000000000505.

Article  CAS  PubMed  Google Scholar 

Abdel-Wahab N, Safa H, Abudayyeh A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer. 2019 Apr 16;7(1):106. https://doi.org/10.1186/s40425-019-0585-1. Erratum in: J Immunother Cancer. 2019 Jun 24;7(1):158.

Lipson EJ, Vincent JG, Loyo M, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res. 2013;1(1):54–63. https://doi.org/10.1158/2326-6066.CIR-13-0034.

Article  CAS  PubMed  Google Scholar 

National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database: NPCR and SEER Incidence – US Cancer Statistics 2001–2015 Public Use Research Database, United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Released June 2018, based on the November 2017 submission. Accessed at www.cdc.gov/cancer/npcr/public-use.

Schmalbach CE, Lowe L, Teknos TN, et al. Reliability of sentinel lymph node biopsy for regional staging of head and neck Merkel cell carcinoma. Arch Otolaryngol Head Neck Surg. 2005;131(7):610–4. https://doi.org/10.1001/archotol.131.7.610.

Article  PubMed  Google Scholar 

Topalian SL, Bhatia S, Amin A, et al. Neoadjuvant nivolumab for patients with resectable Merkel cell carcinoma in the CheckMate 358 Trial. J Clin Oncol. 2020;38(22):2476–87. The results of the CheckMate 358 trial demonstrated a positive effect of neoadjuvant immunotherapy for stage II-IV Merkel cell carcinoma with durable results and improved outcome for responders.

Article  CAS  PubMed  PubMed Central  Google Scholar 

What are basal and squamous cell skin cancers? American Cancer Society. http://www.cancer.org/cancer/skincancer-basalandsquamouscell/detailedguide/skin-cancer-basal-and-squamous-cell-what-is-basal-and-squamous-cell. Accessed March 27January 31, 202118.

Verkouteren JAC, Ramdas KHR, Wakkee M, Nijsten T. Epidemiology of basal cell carcinoma: scholarly review. British Journal of Dermatology. 2017;177:359–72.

Article  CAS  PubMed  Google Scholar 

Wolf DJ, Zitelli JA. Surgical margins for basal cell carcinoma. Arch Dermatol. 1987;123:340–4.

Article  CAS  PubMed  Google Scholar 

Bichakjian C, Armstrong A, Baum C, et al. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol. 2018;78(3):540–59.

Article  Google Scholar 

Molsterd K, Krekels GA, Nieman FH, et al. Surgical excision versus Mohs’ micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years’ follow-up. Lancet Oncol. 2008;9(12):1149–56.

Article  Google Scholar 

Leibobovitch I, Huilgol SC, Selva D, et al. Basal cell carcinoma treated with Mohs surgery in Australia II: outcome at 5-year follow-up. J Am Acad Dermatol. 2005;53(3):452–7.

Article  Google Scholar 

Cameron MC, Lee E, Hibler B, et al. Basal cell carcinoma: contemporary approaches to diagnosis, treatment and prevention. J Am Acad Dermatol. 2019;80(2):321–39.

Article  PubMed  Google Scholar 

Lear JT, Bassett-Seguin N, Kaatz M, et al. Treatment patterns and outcomes for patients with locally advanced basal cell carcinoma before availability of Hedgehog pathway inhibitors: a retrospective chart review. Eur J Dermatol. 2017;27(4):386–92.

Article  PubMed  Google Scholar 

Sekulic A, Migden MR, Oro AE, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17(1):332.

Article  PubMed  PubMed Central  Google Scholar 

Bassett-Seguin N, Hauschild A, Grob JJ, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017;86:334–48.

Article  Google Scholar 

Dummer R, Guminksi A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol. 2020;182(6):1369–78. https://doi.org/10.1111/bjd.18552.

Article  CAS  PubMed  Google Scholar 

Jacobsen AA, Kydd AR, Strassswimmer J, et al. Practical management of the adverse effects of Hedgehog pathway inhibitor therapy for basal cell carcinoma. J Am Acad Dermatol. 2017;76(4):767–8.

Article  PubMed  Google Scholar 

Peer E, Tesanovic S, Aberger F. Next-generation hedgehog/GLI pathway inhibitors for cancer therapy. Cancers. 2019;11(4):538.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bertrand N, Guerreschi P, Basset-Seguin N, et al. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: first results of a multicenter, open-label, phase 2 trial (VISMONEO study): neoadjuvant vismodegib in locally advanced basal cell carcinoma. EClinicalMedicine. 2021;35:100844. https://doi.org/10.1016/j.eclinm.2021.100844.

Article  PubMed  PubMed Central  Google Scholar 

Stratigos AJ, Sekulic A, Peris K, et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):848–57. The results of study 1620 demonstrated the efficacy of cemiplimab in advanced BCC after failure or nontolerance of hedgehog inhibitors.

Article  CAS  PubMed  Google Scholar 

Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018 Dec 1;4(12):1721-1728. https://doi.org/10.1001/jamaoncol.2018.3923. Erratum in: JAMA Oncol. 2018 Dec 1;4(12):1792.

Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093–104. https://doi.org/10.1056/NEJMoa1801946.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Filette J, Andreescu CE, Cools F, et al. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm Metab Res. 2019;51(3):145–56. https://doi.org/10.1055/a-0843-3366.

Article  CAS  PubMed  Google Scholar 

Elghouche AN, Pflum ZE, Schmalbach CE. Immunosuppression impact on head and neck cutaneous squamous cell carcinoma: a systematic review with meta-analysis. otolaryngology--head and neck surgery: official journal of American Academy of Otolaryngology-Head and Neck Surgery 2019;160(3):439–446. (In eng). https://doi.org/10.1177/0194599818808511.

Van Meerhaeghe T, Baurain JF, et al. Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients. Frontiers in Nephrology. 2022;2:1041819. https://doi.org/10.3389/fneph.2022.1041819.